Press Release
RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant
10 years ago
Jun 04, 2014 
VANCOUVER, BC – June 5, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), today announced that it has retained Christina Cameron as its Canadian Investor Relations consultant to create and execute the company’s investor relations strategy within Canada.
Ms. Cameron is a life sciences capital markets expert with over 13 years of experience in investor relations and investment banking. Her extensive network of sell-side, buy-side, retail investors and industry partners will be invaluable to RepliCel as it looks to broaden its Canadian stakeholder base.
Prior to consulting, Ms. Cameron led the in-house investor relations program for Medicago Inc., a TSX listed Canadian life science company, which was recently acquired by Mitsubishi Tanabe Pharma Corporation, a big pharma company. She has also spent 10 years in the life science capital markets industry as a senior member of the TMX Group’s investor relations arm and as a healthcare banker at HSBC Securities and Vengate Capital.
“Ms. Cameron’s experience will be a significant asset to the company as we continue to develop our strategic investor relations program,” stated Gemma Fetterley, VP Finance of RepliCel.
Pursuant to its Stock Option Plan, the Company granted 100,000 options to Ms. Cameron. The options vest over a one year period and are exercisable at $0.65 per share until June 1, 2019.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, pattern baldness and damaged and aging skin. Phase 2 trials are planned for RCT-A-01, a treatment for chronic Achilles tendinosis and RCH-01, a treatment for pattern baldness in 2014. A Phase 1 trial for RCS-01, a treatment for damaged and aging skin is also targeted for 2014. All products are based on RepliCel’s innovative technology which utilizes cells isolated from a patient’s own healthy hair follicles which are then replicated using the company’s proprietary manufacturing and cell expansion platform. Shiseido Company has acquired an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea.
On Behalf of the Board
RepliCel Life Sciences Inc.
/s/ David Hall
David Hall, President and Chief Executive Officer
CONTACT:
Tammey George, Director of Communications
RepliCel Life Sciences
604-248-8696
tg@replicel.com
www.replicel.com
US INVESTOR RELATIONS:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
858-356-5932
robert.uhl@westwicke.com
CANADIAN INVESTOR RELATIONS:
Christina Cameron
christina@clcameron.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
by Topic
DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.